Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)

NCT01167166 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myelocytic Leukemia
Acute Lymphocytic Leukemia
Myeloproliferative Disease
Chronic Myeloid Leukemia

Interventions

DRUG: rigosertib

Sponsor

Traws Pharma, Inc.